Oxford Science Enterprises
Overview
Oxford Science Enterprises (OSE) is a UK-based venture capital firm specializing in spinouts from the University of Oxford. Founded in 2015, OSE partners with the university to identify, fund, and build transformative businesses across life sciences, health tech, and deep tech sectors. The firm has raised over £850 million since its inception, investing in more than 80 companies. OSE's portfolio includes companies like Vaccitech, which developed the Oxford/AstraZeneca COVID-19 vaccine, and Base Genomics, acquired by Exact Sciences for $410 million. The firm provides comprehensive support to its portfolio companies, including strategic business-building, operational support, and access to a global network of entrepreneurs and advisers. OSE's unique partnership with the University of Oxford allows it to access cutting-edge research and collaborate closely with academic founders to commercialize innovative technologies. The firm's patient capital model enables it to support companies through various stages of development, from seed funding to IPOs and trade exits. OSE's commitment to fostering a dynamic ecosystem has led to the creation of over 2,000 highly skilled jobs across its portfolio and the addition of over 55,000 square feet of dedicated lab and start-up space. The firm's diverse investor base includes institutional investors, sovereign wealth funds, family offices, and pension funds, reflecting strong confidence in OSE's ability to translate academic research into successful commercial ventures.
Investment Focus
- Strong link to University of Oxford research
- Innovative technology with potential for global impact
- Experienced management team
- Scalable business model
- Clear path to commercialization
Portfolio Companies
Reach Oxford Science Enterprises directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Oxford Science Enterprises
What sectors does Oxford Science Enterprises invest in?
Oxford Science Enterprises invests in Healthcare, Software, Agriculture, Artificial Intelligence, Pharmaceuticals and Medical Devices, and is based in England, United Kingdom. Oxford Science Enterprises is listed as a venture capital in the ConnectSafely investor database.
What stage does Oxford Science Enterprises invest at?
Oxford Science Enterprises backs companies at Seed, Early Stage, Series A, Series B, Growth and Late Stage, writing cheques of 500K - 25M.
Which regions does Oxford Science Enterprises invest in?
Oxford Science Enterprises invests across United States, United Kingdom, Canada, Germany, Japan and Australia.
Who are the partners at Oxford Science Enterprises?
Team members listed for Oxford Science Enterprises include Ed Bussey (Chief Executive Officer) and Katherine Ward (Chief Commercial Officer, Managing Director UK and Europe).
What companies has Oxford Science Enterprises invested in?
Oxford Science Enterprises's portfolio includes Oxford Nanopore Technologies, Pepgen, Vaccitech, Base Genomics, Ultromics, Alloyed, Metaboards and Evox Therapeutics.
How do I contact Oxford Science Enterprises?
Oxford Science Enterprises's contact details — including LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database
